NPRA Malaysia CTIL & CTX Approval Process

Any sponsor planning to run an interventional clinical trial in Malaysia using an investigational product needs one of two authorisations from Malaysia’s National Pharmaceutical Regulatory Agency (NPRA) before the product can lawfully be imported or manufactured for the study: a Clinical Trial Import Licence (CTIL) or a Clinical Trial Exemption (CTX). This guide explains what NPRA does, when each authorisation applies, how the approval process generally works, and where it fits alongside Malaysia’s separate ethics-review requirement.

What NPRA is and what it regulates

NPRA is the pharmaceutical regulatory body of Malaysia’s Ministry of Health, based in Petaling Jaya, Selangor. It is responsible for the registration and control of drugs, cosmetics, and related products under Malaysian law, including the authorisation needed to bring an unregistered investigational product into the country — or manufacture one locally — solely for use in a clinical trial. The legal basis for CTIL and CTX sits within the Control of Drugs and Cosmetics Regulations 1984 (CDCR 1984), and NPRA publishes the operational detail in a standalone Malaysian Guideline for Application of Clinical Trial Import Licence and Clinical Trial Exemption, which it revises periodically (a 7th edition was published in August 2020, and NPRA has continued to issue further revisions since — always confirm you are working from the current edition posted on npra.gov.my before preparing a submission, since procedural detail changes between editions).

CTIL vs. CTX: which one applies

CTIL and CTX cover the same underlying concern — getting an unregistered investigational product legally into a Malaysian trial site — but they apply to two different supply routes:

Clinical Trial Import Licence (CTIL) — required when the investigational product (including a placebo or comparator) is manufactured outside Malaysia and imported into the country for use in the trial. This is the pathway most multinational, multi-country trials use.
Clinical Trial Exemption (CTX) — required when the investigational product is manufactured locally within Malaysia, solely for the purposes of the clinical trial, rather than imported. A CTX is Malaysia’s route for exempting a locally-made, trial-only product from the standard drug registration pathway that would otherwise apply to a manufactured pharmaceutical.

A single trial can, in principle, need both — for example if some study material is imported while a comparator or matching placebo is manufactured domestically. Sponsors and CROs should confirm the correct pathway (or combination) for each investigational product with NPRA or an experienced local regulatory affairs partner before submission, since misclassifying a product’s supply route is a common source of screening rejections.

Who reviews the application: IPESS

NPRA’s Investigational Product Evaluation and Screening System (IPESS) is the internal review function that receives and evaluates CTIL/CTX dossiers. An IPESS officer first screens the submitted application for completeness and compliance with the current guideline’s documentation checklist; an incomplete dossier is returned to the applicant rather than queued for substantive review, which resets the clock on processing. Once screening is satisfied, applicants are directed to make the applicable payment before substantive technical evaluation of the dossier proceeds.

General approval process

While the exact document checklist and internal review steps are set out in NPRA’s own guideline (and can change between editions), the process generally follows this shape:

Sponsor or local regulatory representative compiles the CTIL or CTX dossier — product and manufacturing information, investigator’s brochure, protocol synopsis, and supporting quality/safety data — per the current guideline’s checklist.
Dossier is submitted to NPRA for IPESS screening.
IPESS confirms completeness; an incomplete submission is returned for correction and resubmission rather than held in queue.
Once screening is satisfied, the applicant proceeds to payment via NPRA’s Finance, Account and Revenue Section.
Substantive technical evaluation of the dossier by NPRA follows.
NPRA issues its decision (approval, rejection, or a request for further information).

Malaysia’s national ethics review runs as a parallel, separate requirement rather than a step inside this sequence — see below.

Processing timelines

Industry regulatory-tracking sources report NPRA processing targets of roughly 45 working days for Phase I trials (including first-in-human studies, and biological, gene-therapy, cell-therapy, and herbal/natural products) and roughly 30 working days for other products and later-phase trials, counted from confirmation that the dossier is complete. CASRAI has not independently verified these specific figures against NPRA’s current primary guideline text, so treat them as a general planning benchmark rather than a committed turnaround — confirm current timelines directly against the latest edition of NPRA’s CTIL/CTX guideline, or with NPRA itself, before building a project plan around them. Timelines run from a “complete” dossier, not from initial submission, so the completeness of the first submission materially affects the real elapsed time.

Ethics review runs separately, through MREC

CTIL/CTX approval from NPRA authorises the import or local manufacture of the investigational product — it is not, by itself, ethics clearance for the trial. Independent ethics committee review in Malaysia is typically obtained through a Medical Research and Ethics Committee (MREC) or an equivalent institutional/independent ethics committee, and trials involving Ministry of Health facilities or investigators are generally also registered through the National Medical Research Register (NMRR). Sponsors should plan CTIL/CTX and ethics review as parallel workstreams with independent timelines and documentation requirements, not a single sequential process — this mirrors how most jurisdictions in the region separate product/import authorisation from research-ethics oversight (see CASRAI’s guide to Singapore’s HSA clinical trial pathways and the BPOM Indonesia approval process for comparable structures).

Practical considerations for sponsors and CROs

Confirm the current guideline edition before drafting a dossier. NPRA revises its CTIL/CTX guideline periodically; process detail, document checklists, and fee schedules in an older edition may no longer be accurate.
Classify each investigational product’s supply route early. Imported vs. locally-manufactured determines CTIL vs. CTX, and getting this wrong at submission is a common cause of screening delay.
Budget for dossier iteration. Because incomplete submissions are returned rather than held in a queue for correction, the real-world timeline to first approval is sensitive to how complete the initial dossier is.
Track MREC/ethics review and NMRR registration on a separate timeline from the CTIL/CTX submission — they are not sequential dependencies of each other in the way some other regulatory systems structure ethics and product approval.
Engage local regulatory affairs expertise for country-specific document formatting, translation, and submission logistics, which matter operationally even where the underlying policy is well documented.

Malaysia in the Southeast Asian regulatory landscape

Malaysia’s NPRA sits alongside a cluster of national regulators that multi-country trial sponsors in the region need to navigate individually, each with its own product-authorisation and ethics-review architecture: Singapore’s Health Sciences Authority (HSA) operates a CTA/CTN/CTC framework, Indonesia’s BPOM administers its own clinical trial approval process (most recently updated under Regulation No. 34 of 2025), and the Philippines FDA runs its process under Administrative Order 2020-0010. None of these frameworks are interchangeable — a CTIL/CTX approval from NPRA has no standing with HSA, BPOM, or the Philippines FDA, and each country’s dossier, timeline, and fee structure has to be prepared and tracked independently for a regional multi-site trial.

Frequently asked questions

What is the difference between CTIL and CTX in Malaysia?

CTIL (Clinical Trial Import Licence) applies when the investigational product is manufactured outside Malaysia and imported for the trial. CTX (Clinical Trial Exemption) applies when the investigational product is manufactured inside Malaysia solely for the trial. The distinction turns on where the product is made, not on the trial phase or product type.

Which body reviews CTIL and CTX applications?

Malaysia’s National Pharmaceutical Regulatory Agency (NPRA), under the Ministry of Health, reviews CTIL and CTX applications through its Investigational Product Evaluation and Screening System (IPESS).

Does CTIL/CTX approval include ethics review?

No. CTIL/CTX authorises the import or local manufacture of the investigational product. Independent ethics review is a separate requirement, typically through a Medical Research and Ethics Committee (MREC) or equivalent, and Ministry of Health-affiliated trials are generally also registered through the National Medical Research Register (NMRR).

How long does NPRA take to approve a CTIL or CTX application?

Industry trackers report benchmarks of roughly 45 working days for Phase I and related higher-risk product categories and roughly 30 working days for other products and phases, measured from a complete dossier. CASRAI has not independently verified these figures against NPRA’s primary guideline text — confirm current timelines directly with NPRA before relying on them for planning.

What is the legal basis for CTIL and CTX?

CTIL and CTX sit within Malaysia’s Control of Drugs and Cosmetics Regulations 1984 (CDCR 1984), with operational requirements set out in NPRA’s periodically-revised Malaysian Guideline for Application of Clinical Trial Import Licence and Clinical Trial Exemption.

Can a single trial need both a CTIL and a CTX?

Yes, in principle — for example where an active investigational product is imported but a locally-manufactured placebo or comparator is also used. Each product’s supply route should be classified individually against the CTIL/CTX criteria.

NPRA Malaysia Clinical Trial Import Licence (CTIL) and Clinical Trial Exemption (CTX): Approval Process